Clinical Trials

The aim of this study is to determine which clinical characteristics are associated with diplopia in patients with epiretinal membranes. 

The GUARD Trial is a multi-center adaptive Phase 3 clinical trial of repeated intravitreal injections of ADX-2191 for the prevention of proliferative vitreoretinopathy.

The purpose of this study is to review the management and outcomes of patients who had vitreoretinal surgery at the Mayo Clinic. A search will be made using relevant ICD-9 codes and surgical databases. Presenting symptoms, visual acuity, management strategies, visual and anatomic outcomes will be reviewed.

The primary objective of this study is to evaluate mean change in best-corrected visual acuity (BCVA) of RGX-314 relative to ranibizumab at Week 38.

Second objectives of this study are to evaluate the safety and tolerability of RGX-314 through Week 102, to evaluate the effect of RGX-314 relative to ranibizumab on BCVA, to evaluate the effect of RGX-314 relative to ranibizumab on central retinal thickness (CRT) as measured by spectral domain-ocular coherence tomography (SD-OCT), to evaluate the effect of RGX-314 relative to ranibizumab on center point thickness (CPT) as measured by SD-OCT, to assess the need for supplemental anti-vascular endothelial growth factor ...

The purpose of this study is to learn about cell function in different tissues of the eye in various ocular diseases via transcriptomics in the Mayo Clinic laboratory.

The purpose of this study is to identify persons with MacTel Type 2, and their affected family members to create a registry of persons with MacTel Type 2. This registry will be used to study participants with MacTel Type 2 now and may be used in the future to identify persons to be in a study that may help find a way to prevent or treat this eye condition. We also wish to keep in contact with persons who have been told by their MacTel doctor that they have MacTel Type 2.

SCORE2 is a multicenter, prospective, randomized, phase III clinical trial in which all participants enrolled will be followed for 12 months. SCORE2 is designed as a non-inferiority trial, with study eyes randomized to intravitreal bevacizumab (1.25 mg) every 4 weeks vs. intravitreal aflibercept (2.0 mg) every 4 weeks. SCORE2 aims to determine if bevacizumab is non-inferior to aflibercept for the treatment of macular edema associated with central retinal vein occlusion (CRVO), with the primary outcome of visual acuity measured at Month 6.

The Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial will compare the relative efficacy and safety of intravitreal methotrexate, intravitreal ranibizumab, and the intravitreal dexamethasone implant for the treatment of uveitic macular edema persisting or reoccurring after an intravitreal corticosteroid injection. MERIT is a parallel design (1:1:1), randomized comparative trial with an anniversary close-out at the 6 month clinic visit. The primary outcome is percent change in central subfield thickness from the baseline OCT measurement to the 12 week visit.

The purpose of this study is to determine if a relay lens and right angle mirror can be used in conjunction with an FDA-approved optical coherence tomography (OCT) unit to allow imaging in supine patients.

The purpose of this study is to evaluate the ability of appropriately-trained family physicians to screen for and identify Diabetic Retinopathy using retinal camera and, secondarily, to describe patients’ perception of the convenience and cost-effectiveness of retinal imaging.